BACKGROUND: Cancer is a deadly malignant disease and is prevalent in Sub Saharan
Africa. The North East part of Nigeria in particular and the country, in general, are struggling …

Background Imatinib is the gold standard for the treatment of all phases of Philadelphia
positive Chronic Myeloid Leukemia (CML). During treatment, patients may develop …

Objectives: This study aimed to examine the prognostic value of anemia for the diagnosis of
chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib. Methods: One …

Polymorphisms in CYP2C8 and CYP3A5 genes have implications for responses elicited by
the ingestion of some xenobiotics, the metabolism of which are mediated by these enzymes …

Thyroid dysfunction has been reported as an adverse effect of imatinib mesylate. However,
the risk factors associated with this adverse effect in CML patients have not been elucidated …

Chronic myeloid leukemia (CML) is an age-dependent blood malignancy. Like many other
age-dependent human diseases, laboratory animal research of CML uses young mice that …

The distribution of BCR–ABL1 transcript variants e13a2 (“b2a2”) and e14a2 (“b3a2”) in
Nigerians with chronic myeloid leukemia (CML) had not been previously studied. In addition …

BACKGROUND: Thyroid toxicity has been reported with tyrosine kinase inhibitors (TKIs)
such as sunitinib and sorafenib, targeting angiogenic tyrosine kinase receptors. However …

Background: Chronic myeloid leukemia (CML) is a clonal myelo-proliferative disorder of a
pluripotent stem cell. Aim: To find the frequency of low, intermediate and high risk category …

Background: Chronic myeloid leukemia (CML) is a bi-or triphasic disease comprising of the
chronic phase (present at diagnosis in approximately 85% of patients) which can easily be …